Aralez Reports Fourth Quarter And Full-Year 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Aralez Pharma (ARLZ) Misses Q4 EPS by 12c; Announces Resubmission of YOSPRALA NDA
March 15, 2016 7:52 AM EDTAralez Pharma (NASDAQ: ARLZ) reported Q4 EPS of ($0.40), $0.12 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $5.97 million versus the consensus estimate of $10.41 million.
GUIDANCE:
Aralez Pharma sees FY2016 revenue of $48-58 million, versus the consensus of $54.8 million.
Update:
Aralez also announced that it has resubmitted to the U.S. Food and Drug Administration ("FDA") the New Drug Application ("NDA") for its investigational candidate, YOSPRALA (PA32540/PA8140) for the secondary... More
